News Search Results
Apr 29, 2025, 02:49 ET One of the world's most prestigious cancer centers adopts Sectra for integrated diagnostics and improved patient care
improving patient care. The center will initially utilize Sectra's modules for radiology, breast imaging, cardiology, pathology and ophthalmology, all unified within a single platform. A single system for multiple specialties will provide them with a comprehensive overview of the patient imaging
More news about: Sectra
Apr 28, 2025, 08:00 ET Celltrion to present six abstracts in inflammatory bowel disease (IBD) at 2025 Digestive Disease Week® (DDW)
monoclonal antibody biosimilar. Our global pharmaceutical portfolio addresses a range of therapeutic areas including immunology, oncology, hematology, ophthalmology and endocrinology. Beyond biosimilar products, we are committed to advancing our pipeline with novel drugs to push the boundaries of scientific
More news about: Celltrion
Apr 28, 2025, 07:00 ET InMode Reports First Quarter 2025 Financial Results; Quarterly Revenue of $77.9 Million Represents 3% Year-Over-Year Decrease
technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode, please visit www.inmodemd.com. Forward-Looking
More news about: InMode Ltd.
Apr 28, 2025, 04:00 ET Bone Health: Biocon Biologics Receives Positive CHMP Opinions for Biosimilar Denosumab in Europe
and Japan. It has a pipeline of 12 biosimilar assets under development across diabetology, oncology, immunology, ophthalmology, and other non-communicable diseases. The Company has many 'firsts' to its credit in the biosimilars industry. As part of its environmental, social
More news about: Biocon Biologics
Apr 28, 2025, 04:00 ET Bone Health: Biocon Biologics Receives Positive CHMP Opinions for Biosimilar Denosumab in Europe
and Japan. It has a pipeline of 12 biosimilar assets under development across diabetology, oncology, immunology, ophthalmology, and other non-communicable diseases. The Company has many 'firsts' to its credit in the biosimilars industry. As part of its environmental, social
More news about: Biocon Biologics
Apr 27, 2025, 20:00 ET 2025 AACR | Innovent Presents Preclinical Data of Multiple Novel Molecules including Bispecific and Tri-specific Antibodies and Bispecific ADCs
that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that preclinical data on multiple novel bispecific antibodies, tri-specific antibodies as well as bispecific
More news about: Innovent Biologics
Apr 25, 2025, 22:19 ET Formosa Pharmaceuticals and Saval Corporation Announce Licensing Agreement for Clobetasol Propionate Ophthalmic Suspension for the Treatment of Post-Operative Inflammation and Pain
convenient dosing regimen (4 to 6 times daily). "We are pleased that Saval has identified APP13007 as a worthy therapy to include in their ophthalmology core business unit. Saval's vast network throughout Latin America will guarantee that patients recovering from
More news about: Formosa Pharmaceuticals Inc.,
Apr 25, 2025, 16:19 ET Nanoscope Therapeutics Announces Participation at Eyecelerator® and ARVO 2025 Annual Meetings
The Association for Research and Vision in Ophthalmology (ARVO) 2025 annual meetings. Nanoscope's presentations will be centered around 126-week outcomes following treatment with its
More news about: Nanoscope Therapeutics
Apr 24, 2025, 12:00 ET VivaVision Announces Positive Topline Results from Phase 2 Trial of VVN461 for Non-Infectious Anterior Uveitis
very significant and potentially disruptive progress in treating uveitis." said Professor. Liu Yang, Director of Ophthalmology at Peking University First Hospital, "We hope that this safe, highly efficacious and accessible non-steroidal medicine,
More news about: VivaVision Biotech
Apr 24, 2025, 08:00 ET Stealth BioTherapeutics to Present New Bevemipretide Data at ARVO Annual Meeting
for diseases involving mitochondrial dysfunction, today announced several upcoming presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, which is being held May 4-8, 2025, in Salt Lake City. These
More news about: Stealth BioTherapeutics Inc.
Apr 24, 2025, 08:00 ET Beacon Therapeutics Announces ARVO 2025 Presentation on Preliminary 6-Month Data from its Phase 2 DAWN Trial of laru-zova in Patients with X-linked Retinitis Pigmentosa (XLRP)
program, laru-zova (laruparetigene zovaparvovec), in patients with X-linked retinitis pigmentosa (XLRP) at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting being held May 4-8, 2025 in Salt Lake City.
More news about: Beacon Therapeutics
Apr 24, 2025, 08:00 ET Mabwell to Present Clinical Data of 9MW2821 Combined with Toripalimab in Patients with UC in an Oral Presentation at 2025 ASCO
R&D engine, including 12 novel drug candidates and 4 biosimilars. We focus on the therapeutic areas of oncology, immunology, bone disorders, ophthalmology, hematology and infectious diseases, etc. Of these, 3 products have been approved and commercialized, 1 product has been filed for market approval,
More news about: Mabwell
Apr 24, 2025, 02:28 ET Sun Pharma and Moebius Medical Announce Dual Publications on MM-II's Phase 2b Clinical Trial Results and Mechanism of Action in Osteoarthritis and Cartilage
company in the U.S. as well as global emerging markets. Sun Pharma's high-growth global specialty portfolio spans innovative products in dermatology, ophthalmology, and onco-dermatology and accounts for over 18% of company sales. The company's vertically integrated operations deliver high-quality medicines,
More news about: Moebius
Apr 23, 2025, 19:00 ET Seven Oral Presentations: Innovent to Present Breakthrough Clinical Data of IBI363（PD-1/IL-2α-bias）and Other Novel Drug Candidates at the 2025 ASCO Annual Meeting
that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that clinical data for its innovative bispecific antibodies and ADC molecules, including oral presentations
More news about: Innovent Biologics
Apr 23, 2025, 16:45 ET Avirmax Biopharma Inc. to Present at the 2025 ARVO Annual Meeting in Salt Lake City
the 2025 Association for Research in Vision and Ophthalmology (ARVO) annual meeting in Salt Lake City, Utah, May 4 - 8, 2025. ARVO is the largest international society dedicated to ophthalmology and other vision-related topics.
More news about: Avirmax
Apr 23, 2025, 06:52 ET Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection at the 2025 Digestive Disease Week (DDW) Annual Meeting
segment's areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, nephrology, pulmonology and ophthalmology; neonatal respiratory critical care therapies; and gastrointestinal products. Its Specialty Generics reportable segment includes specialty generic
More news about: Mallinckrodt plc
Apr 22, 2025, 13:10 ET ZEN core now available for all ZEISS scanning electron microscopes
assurance, microscopy solutions for the life sciences and materials research, and medical technology solutions for diagnostics and treatment in ophthalmology and microsurgery. The name ZEISS is also synonymous with the world's leading lithography optics, which are used by the chip industry to manufacture
More news about: ZEISS Research Microscopy Solutions
Apr 22, 2025, 09:23 ET NanoDrops Names Daria Lemann-Blumenthal as CEO
the company to the next level of clinical studies and industry engagement." Lemann-Blumenthal, who has two decades of experience in the ophthalmology industry and holds an LL.B. and executive MBA, will be joining NanoDrops co-founder and chief medical officer Prof. David
More news about: NanoDrops
Apr 22, 2025, 09:00 ET Luminopia Announces FDA Clearance for Patients with Amblyopia Aged 8 to 12 Years
vision. "It's rare for the FDA to provide clearance based on RWE alone and, as far as we're aware, this is the first instance of it being done in ophthalmology. The FDA's decision is a testament to the rigorous design of the PUPiL Registry and the strength of our product's safety and efficacy," said
More news about: Luminopia
Apr 21, 2025, 10:00 ET Perfuse Therapeutics Announces Oral Presentation on PER-001 Intravitreal Implant for Glaucoma at the Association for Research in Vision and Ophthalmology (ARVO) Meeting
announced that an oral presentation on PER-001 intravitreal implant for glaucoma has been accepted for the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2025 being held May 4 to May 8, 2025, in Salt Lake City, Utah.
More news about: Perfuse Therapeutics
Apr 17, 2025, 09:43 ET Syrian American Doctors Lead Medical Missions in Jordan and Newly Liberated Syria
hospitals to deliver direct care to vulnerable Syrian and Palestinian refugees. The team includes experts in Dental, Cardiology, Orthopedics, Ophthalmology, ENT, Pulmonary, Obstetrics & Gynecology, Pediatrics, Internal Medicine, Radiology, Plastic Surgery, and Gastroenterology. Over
More news about: The Syrian American Medical Society
Apr 17, 2025, 09:00 ET ZEISS continues to drive digital era forward in ophthalmology; celebrates 2 million digitally-planned cataract cases in the U.S. alone
significant benefits of using digital workflows as the backbone of their medical practices," says Magnus Reibenspiess, Head of Strategic Business Unit Ophthalmology at ZEISS Medical Technology. "ZEISS has much to celebrate at ASCRS this year, including our continued U.S. leadership in digital innovation and
More news about: Carl Zeiss Meditec AG
Apr 17, 2025, 09:00 ET ZEISS continues to drive digital era forward in ophthalmology; celebrates 2 million digitally-planned cataract cases in the U.S. alone
significant benefits of using digital workflows as the backbone of their medical practices," says Magnus Reibenspiess, Head of Strategic Business Unit Ophthalmology at ZEISS Medical Technology. "ZEISS has much to celebrate at ASCRS this year, including our continued U.S. leadership in digital innovation and
More news about: Carl Zeiss Meditec AG
Apr 17, 2025, 08:00 ET Powered Research Announces Launch of Oncology Preclinical Services at AACR Annual Meeting 2025 at Booth #3154 in Chicago
Known for over a decade as the leading preclinical Ophthalmology CRO, now extending our high-quality standards to Oncology. RESEARCH TRIANGLE PARK, N.C., April
More news about: Powered Research, LLC
Apr 15, 2025, 17:13 ET Parker Waichman LLP Files One of the First NAION Eye Injury Cases against Novo Nordisk in the Superior Court of New Jersey, Middlesex County
concerns about the failure of drug manufacturers to warn consumers and medical professionals about these risks. A 2025 study published in JAMA Ophthalmology examined nine patients who developed optic nerve disorders after using GLP-1 medications, with the majority suffering
More news about: Parker Waichman LLP